Tirzepatide Cost & Price Guide

Also sold as: Mounjaro, Mounjaro KwikPen

As a brand-name drug with no generic, Mounjaro is expensive. Patients should look for manufacturer savings programs or patient assistance programs to reduce costs.

Typical Cost
$1,000–$1,200/month

Per month, without insurance

Generic
Not Available

Only brand-name versions currently available

Coupons
Available

Discount coupons may reduce out-of-pocket costs

Cost Overview

As a brand-name drug with no generic, Mounjaro is expensive. Patients should look for manufacturer savings programs or patient assistance programs to reduce costs.

Generic vs. Brand-Name Price

VersionTypical Monthly CostNotes
Mounjaro(brand)$1,000–$1,200/monthCheck manufacturer patient assistance programs
Mounjaro KwikPen(brand)$1,000–$1,200/monthCheck manufacturer patient assistance programs

Ways to Save on Tirzepatide

Prescription Discount Cards

Free discount programs like GoodRx, RxSaver, and NeedyMeds can reduce the cost of tirzepatide at most pharmacies. Compare prices before filling.

90-Day Supply

Ordering a 90-day supply through a mail-order pharmacy often costs less per dose than monthly fills. Check with your insurance plan or pharmacy benefit manager.

Patient Assistance Programs

If you're uninsured or underinsured, the manufacturer may offer a patient assistance program (PAP) that provides tirzepatide at low or no cost. Visit NeedyMeds.org or the manufacturer's website.

Insurance Coverage

Most insurance plans, including Medicare Part D and Medicaid, cover tirzepatide . Coverage and copay amounts vary by plan tier and formulary. Contact your insurance provider or check your plan's drug formulary to confirm coverage.

Medicare Part D
Usually covered; tier varies by plan
Medicaid
Generally covered; check your state plan
Commercial Insurance
Typically covered; copay varies

Find the Best Price

Frequently Asked Questions About Tirzepatide Cost

What is TIRZEPATIDE used for?

1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )

What is the recommended dosage for TIRZEPATIDE?

2 DOSAGE AND ADMINISTRATION The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. ( 2.1 ) After 4 weeks, increase to 5 mg injected subcutaneously once weekly. ( 2.1 ) If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. ( 2.1 ) Maximum dosage ( 2.1 ): Adults: 15 mg subcutaneously once weekly. Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly. Administer once weekly at any time of day, with or without meals. ( 2.2 ) Inject subcutaneously in the abdomen, thigh, or…

How does TIRZEPATIDE work?

12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.

Who should not take TIRZEPATIDE?

4 CONTRAINDICATIONS MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO [see Warnings and Precautions ( 5.4 )] . Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type…

More Tirzepatide Information

Medical Disclaimer

The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.